ZOETIS INC (ZTS)

US98978V1035 - Common Stock

173.05  -3.82 (-2.16%)

ZOETIS INC

NYSE:ZTS (9/27/2023, 12:24:30 PM)

173.05

-3.82 (-2.16%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/bmo
Earnings (Next)11-01 2023-11-01/bmo
Ins Owners0.04%
Inst Owners195.63%
Market Cap79.66B
Shares460.32M
PE34.06
Fwd PE28.14
Dividend Yield0.85%
Analysts81
IPO02-01 2013-02-01
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ZTS Daily chart

Company Profile

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 13,800 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. The company commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The firm operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The firm market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.

Company Info

ZOETIS INC

10 Sylvan Way

Parsippany NEW JERSEY 07054

P: 19738227000.0

CEO: Kristin C. Peck

Employees: 13800

Website: https://www.zoetis.com/

ZTS News

News Image5 hours ago - Zoetis Inc.Zoetis to Host Webcast and Conference Call on Third Quarter 2023 Financial Results
News Image11 days ago - PR LeapDMF Group and Corporate Finance Associates acted as the exclusive M&A advisors of adivo

Los Angeles, California 9-16-2023, DMF Group, Frankfurt, and its partner Corporate Finance Associates Worldwide (CFAW), Los Angeles, exclusively advised the shareholders of adivo GmbH, Puchheim near Munich, on the sale of 100% of their shares to Zoetis Inc. (NYSE: ZTS), Parsippany, NJ, near New York.

News Image14 days ago - Market News VideoFirst Week of September 15th Options Trading For Zoetis (ZTS)
News Image17 days ago - Seeking AlphaHSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead (NYSE:IQV)

HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its buy ratings list. Read more here.

News Image20 days ago - The Motley Fool4 Top Dividend Growth Stocks of the S&P 500 That Have Major Long-Term Potential for Investors

Don't let their diminutive-looking yields fool you -- these stocks are four of the fastest dividend growers in the S&P 500.

News Image20 days ago - Zoetis Inc.Zoetis Foundation Announces $2.6 Million in Grants to Advance Opportunities for Veterinarians and Livestock Farmers

ZTS Twits

Here you can normally see the latest stock twits on ZTS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example